B+
Bull case
0%
Probability
Target price
$34.00
+19.3% vs current
ARQT
Arcutis BiotherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
0%
Probability
Target price
$28.00
-1.7% vs current
B-
Bear case
0%
Probability
Target price
$20.00
-29.8% vs current
AI sentiment snapshot
Latest data as of 2026-06-30
Recent news sentiment (30D)
+0.5
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+41.8
Score
AI commentary
Headline tone improved with the June 29, 2026 FDA approval for pediatric psoriasis, but the memo remains a tentative monitoring view rather than a standard-conviction thesis. The packet's deterministic prior is negative across 5d to 120d horizons, analyst-target breadth is unavailable, social context is absent, and peer read-through is loose. The next validation points are whether pediatric label expansion and sales-force investment convert into durable ZORYVE demand, gross-to-net stability, and operating leverage rather than a one-day regulatory headline.
RankAlpha Sentiment Codex - 2026-06-30
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-29eventFDA approved pediatric plaque-psoriasis label expansion for ZORYVE cream 0.3%High impact
Arcutis announced on June 29, 2026 that FDA approved ZORYVE cream 0.3% for plaque psoriasis in children as young as age 2, extending the franchise into a younger pediatric cohort and adding a fresh commercial launch vector [#IR-2026-06-29].
2026-12-15catalystPipeline readouts beyond the core franchise can widen or cap the multipleHigh impact
Management said Phase 2 proof-of-concept data for vitiligo are expected in Q4 2026 and hidradenitis suppurativa in Q1 2027, while ARQ-234 has entered Phase 1a/1b; these programs matter for proving Arcutis is more than a single-franchise commercial story [#PR-EARNINGS-2026-05-07].
2026-12-31catalystCommercial execution against 2026 revenue guidance remains the core value driverHigh impact
Q1 2026 net product revenue was $105.4M, up 65% year over year, and management maintained 2026 net product revenue guidance of $480M-$495M while noting completed dermatology sales-force expansion, primary-care/pediatrics build-out, and positive operating cash flow; however Q1 sales were down 17% sequentially due to deductible resets and insurance changes [#PR-EARNINGS-2026-05-07].
Recommendation
N/A
No formal recommendation provided.
As of 2026-06-30 • Updated nightlySource: Internal modelMethodology